AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30227969 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey plus oral acyclovir
Number of subjects: 100
Study 30227969 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir alone
Number of subjects: 100
Study 27997586 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntometrine® administration
Number of subjects: 316
Study 27997586 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural use
Number of subjects: 316
Study 25749598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management
Number of subjects: 114
Study 25749598 — intervention group
Group type: COMPARATOR
Intervention: Cancer wellness and education program
Number of subjects: 114
Study 22819406 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 shocks per minute (group 1)
Number of subjects: 206
Study 22819406 — intervention group
Group type: COMPARATOR
Intervention: 120 shocks per minute (group 2)
Number of subjects: 206
Study 20053811 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 20
Study 20053811 — intervention group
Group type: COMPARATOR
Intervention: Gadodiamide
Number of subjects: 20
Study 18682012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle-change programme (increased exercise and diet change: either reduction in glycaemic load or reduced-fat diet)
Number of subjects: 33
Study 18682012 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 33
Study 18682012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic-load diet
Number of subjects: 33
Study 18682012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 33
Study 15718828 — intervention group
Group type: EXPERIMENTAL
Intervention: Proview eye pressure monitor (PEPM)
Number of subjects: 70
Study 12581080 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 3% diclofenac in 2.5% hyaluronan gel
Number of subjects: 150
Study 12581080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle only, hyaluronan gel)
Number of subjects: 150
Study 9862835 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI for solid meal (SM)
Number of subjects: 8
Study 9862835 — intervention group
Group type: COMPARATOR
Intervention: Scintigraphy for solid meal (SM)
Number of subjects: 8
Study 9862835 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI for liquid meal (LM)
Number of subjects: 8
Study 9862835 — intervention group
Group type: COMPARATOR
Intervention: Scintigraphy for liquid meal (LM)
Number of subjects: 8
Study 8501574 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS hyperimmune IVIG, 500 mg/kg
Number of subjects: 20
Study 8501574 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS hyperimmune IVIG, 250 mg/kg
Number of subjects: 20
Study 8501574 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS hyperimmune IVIG, 100 mg/kg
Number of subjects: 20
Study 8501574 — intervention group
Group type: COMPARATOR
Intervention: Standard IVIG, 500 mg/kg
Number of subjects: 20
Study 8501574 — intervention group
Group type: COMPARATOR
Intervention: Standard IVIG
Number of subjects: 20
Study 8501574 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS hyperimmune IVIG
Number of subjects: 20
Study 3326679 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release hydralazine BID
Number of subjects: 29
Study 3326679 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release hydralazine TID
Number of subjects: 29
Study 3326679 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release hydralazine QD
Number of subjects: 29
Study 3326679 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 29
Study 3326679 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (80 mg/day of nadolol)
Number of subjects: 29
Study 30742378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefradoz 1 capsule 2 times a day (n=45)
Number of subjects: 80
Study 30742378 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=35)
Number of subjects: 80
Study 27784460 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment (cinobufacini injection, herbal decoction, and Chinese acupoint application)
Number of subjects: 64
Study 27784460 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 64
Study 27784460 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 64
Study 27784460 — intervention group
Group type: EXPERIMENTAL
Intervention: sCTLA-4 levels and treatment regimen
Number of subjects: 64
Study 25886416 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine group (3 mg bupivacaine + 10 ug fentanyl)
Number of subjects: 50
Study 25886416 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine group (20 mg lidocaine + 25 ug fentanyl)
Number of subjects: 50
Study 23218184 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/day FAc inserts
Number of subjects: 44
Study 23218184 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg/day FAc inserts
Number of subjects: 44
Study 23218184 — intervention group
Group type: EXPERIMENTAL
Intervention: FAc implants
Number of subjects: 44
Study 22333199 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI plus a low concentration of sevoflurane inhalation induction (Group A)
Number of subjects: 90
Study 22333199 — intervention group
Group type: COMPARATOR
Intervention: Ketamine plus propofol TCI (Group B)
Number of subjects: 90
Study 22333199 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl plus propofol TCI (Group C)
Number of subjects: 90
Study 19454182 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol plus ibuprofen
Number of subjects: 0
Study 19454182 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol alone
Number of subjects: 0
Study 19454182 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 0
Study 16682486 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet supplemented with wheat bran (24 g/day)
Number of subjects: 9
Study 15129696 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-TRODAT-1 SPET imaging
Number of subjects: 188
Study 11413109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenovil 4 microg/kg QD
Number of subjects: 65
Study 11413109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenovil 8 microg/kg TIW
Number of subjects: 65
Study 11413109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 10450618 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-based intervention
Number of subjects: 50
Study 10450618 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 50
Study 8002836 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil removal
Number of subjects: 222
Study 8002836 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil retention
Number of subjects: 222
Study 2729168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Cu fructose diet
Number of subjects: 19
Study 2729168 — intervention group
Group type: COMPARATOR
Intervention: Low-Cu cornstarch diet
Number of subjects: 19
Study 4699595 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg betamethasone in saline
Number of subjects: 11
Study 4699595 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 11
Study 31760462 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient management
Number of subjects: 395
Study 31188172 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plus 2 mL distilled water (Lido)
Number of subjects: 75
Study 31188172 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plus 2 mL (8 mg) dexamethasone (Dexa)
Number of subjects: 75
Study 31188172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus 2 mL (1 µg/kg) dexmedetomidine (Dexm)
Number of subjects: 75
Study 28724657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL) 20 g/d, 118 kcal
Number of subjects: 4011
Study 28724657 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA; 60 mg Fe + 400 μg folic acid/d)
Number of subjects: 4011
Study 26458895 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily for 14 days
Number of subjects: 4400
Study 26458895 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg daily for 14 days
Number of subjects: 4400
Study 23977723 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrylated high amylose maize starch (HAMSB) 20 g twice daily for 28 days
Number of subjects: 41
Study 23977723 — intervention group
Group type: COMPARATOR
Intervention: Low amylose maize starch (LAMS)
Number of subjects: 41
Study 21944077 — intervention group
Group type: COMPARATOR
Intervention: Sedentary participants
Number of subjects: 121
Study 21944077 — intervention group
Group type: EXPERIMENTAL
Intervention: Old players
Number of subjects: 121
Study 21944077 — intervention group
Group type: EXPERIMENTAL
Intervention: Young players vs Old players
Number of subjects: 121
Study 21944077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary vs Old players
Number of subjects: 121
Study 21944077 — intervention group
Group type: EXPERIMENTAL
Intervention: Young vs Old players
Number of subjects: 121
Study 18006188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg intravenously
Number of subjects: 77
Study 18006188 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 20 mg intravenously
Number of subjects: 77
Study 16804032 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency exposure (1,800 MHz, Specific Absorption Rate 2 W/kg) with mitogenic stimulation
Number of subjects: 0
Study 16804032 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 0
Study 12951616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UCA) 10 mg/kg/day until surgery, n=30
Number of subjects: 72
Study 12951616 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=42
Number of subjects: 72
Study 12951616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UCA) treatment duration
Number of subjects: 72
Study 10981524 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula (Nan HA)
Number of subjects: 478
Study 10981524 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed casein formula (Nutramigen)
Number of subjects: 478
Study 10981524 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey formula (Profylac)
Number of subjects: 478
Study 10981524 — intervention group
Group type: COMPARATOR
Intervention: Exclusively breast-fed infants
Number of subjects: 478
Study 10981524 — intervention group
Group type: COMPARATOR
Intervention: Infants fed extensively hydrolyzed formula (Nutramigen or Profylac)
Number of subjects: 478
Study 10981524 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants fed partially hydrolyzed formula (Nan HA)
Number of subjects: 478
Study 9101380 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0
Study 9101380 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-supplementation follow-up
Number of subjects: 0
Study 9101380 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression models
Number of subjects: 0
Study 8240057 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 525
Study 8240057 — intervention group
Group type: COMPARATOR
Intervention: Non-Heparin
Number of subjects: 525
Study 3298408 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha-interferon treatment (doses ranging from 18 to 50 million units/m2, 3 times per week)
Number of subjects: 44
Study 3298408 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha-interferon treatment (doses ranging from 2.5 to 10 million units/m2)
Number of subjects: 44
Study 3298408 — intervention group
Group type: COMPARATOR
Intervention: Untreated carriers (control group)
Number of subjects: 44
Study 3298408 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 44
Study 29574606 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 20
Study 29574606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25828692 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg pre-emptive administration)
Number of subjects: 103
Study 25828692 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (post-operative treatment)
Number of subjects: 103
Study 25828692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pre-emptive administration)
Number of subjects: 103
Study 25828692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (post-operative treatment)
Number of subjects: 103
Study 25828692 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib and Placebo (sensory perception)
Number of subjects: 103
Study 25436273 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management programme (diaphragmatic breathing, progressive muscle relaxation, guided imagery, twice a day)
Number of subjects: 60
Study 25436273 — intervention group
Group type: COMPARATOR
Intervention: Not undergoing the stress management programme (control group)
Number of subjects: 60
Study 23244805 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported frequency of hypoglycemia
Number of subjects: 3059
Study 23244805 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectively confirmed hypoglycemic events (0, ≥1)
Number of subjects: 3059
Study 20184604 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic mixture (extensively hydrolysed formula with Bifidobacterium breve M‐16V and a galacto‐/fructooligosaccharide mixture)
Number of subjects: 90
Study 20184604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same formula without synbiotics)
Number of subjects: 90
Study 20184604 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic mixture
Number of subjects: 90
Study 20184604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18596069 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (group 2)
Number of subjects: 120
Study 18596069 — intervention group
Group type: COMPARATOR
Intervention: No HAART (group 3)
Number of subjects: 120
Study 18596069 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected (group 1)
Number of subjects: 120
Study 16052595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 4.5 mg orally every evening
Number of subjects: 60
Study 16052595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16052595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 60
Study 12296613 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (Reminyl®)
Number of subjects: 0
Study 10403354 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (erythromycin, doxycycline, trimethoprim/sulfamethoxazole)
Number of subjects: 8
Study 8840339 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a violent movie
Number of subjects: 20
Study 8840339 — intervention group
Group type: COMPARATOR
Intervention: Viewing a neutral movie
Number of subjects: 20
Study 1929761 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 52
Study 1929761 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 52
Study 7338577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1 to 2 mg daily for three days)
Number of subjects: 20
Study 7338577 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (80 mg daily for three days)
Number of subjects: 20
Study 31486406 — intervention group
Group type: EXPERIMENTAL
Intervention: Online coaching via real-time chat messages
Number of subjects: 793
Study 31486406 — intervention group
Group type: COMPARATOR
Intervention: Self-guided program (control group)
Number of subjects: 793
Study 29058111 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR
Number of subjects: 16
Study 29058111 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 16
Study 26049614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine
Number of subjects: 40
Study 26049614 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine with felypressin
Number of subjects: 40
Study 23876569 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation therapy
Number of subjects: 102
Study 23876569 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy
Number of subjects: 102
Study 21352592 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus adalimumab
Number of subjects: 402
Study 21352592 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 402
Study 19697195 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg natural micronised progesterone intravaginally once daily from 20‐24 weeks' gestation until 36 weeks
Number of subjects: 100
Study 19697195 — intervention group
Group type: COMPARATOR
Intervention: Control group (no progesterone)
Number of subjects: 100
Study 19697195 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg natural micronised progesterone intravaginally
Number of subjects: 100
Study 17084030 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathel
Number of subjects: 0
Study 17084030 — intervention group
Group type: COMPARATOR
Intervention: Omiderm
Number of subjects: 0
Study 14704911 — intervention group
Group type: EXPERIMENTAL
Intervention: PHMB-based system
Number of subjects: 0
Study 14704911 — intervention group
Group type: COMPARATOR
Intervention: PQ-based system
Number of subjects: 0
Study 11694928 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-deficient knees
Number of subjects: 44
Study 11694928 — intervention group
Group type: COMPARATOR
Intervention: ACL-intact knees
Number of subjects: 44
Study 9215435 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional case-control studies
Number of subjects: 0
Study 9215435 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-crossover design
Number of subjects: 0
Study 9215435 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid designs (case-control, case-crossover, cohort)
Number of subjects: 0
Study 8480824 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of fluoxetine
Number of subjects: 382
Study 8480824 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of fluoxetine
Number of subjects: 382
Study 8480824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 3505173 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II gastrojejunostomy
Number of subjects: 20
Study 3505173 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastrojejunostomy
Number of subjects: 20
Study 31768470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay navigator-led early palliative care coaching intervention
Number of subjects: 0
Study 31768470 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29143427 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program using printed educational material
Number of subjects: 17
Study 29143427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 17
Study 27113608 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (Group 1)
Number of subjects: 33
Study 27113608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle osteoarthritis (Group 2)
Number of subjects: 33
Study 24703723 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-containing treatment
Number of subjects: 0
Study 24703723 — intervention group
Group type: COMPARATOR
Intervention: Luminal group
Number of subjects: 0
Study 24703723 — intervention group
Group type: COMPARATOR
Intervention: HR-negative disease
Number of subjects: 0
Study 22661453 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo metered-dose inhaler
Number of subjects: 21
Study 22661453 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 21
Study 22661453 — intervention group
Group type: COMPARATOR
Intervention: Inhaler therapy (informed it was inert)
Number of subjects: 21
Study 20226408 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D‐SHG
Number of subjects: 70
Study 20226408 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐SHG
Number of subjects: 70
Study 20226408 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic hysteroscopy
Number of subjects: 70
Study 18784099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical lavage and arthroscopic debridement together with optimized physical and medical therapy
Number of subjects: 178
Study 18784099 — intervention group
Group type: COMPARATOR
Intervention: Physical and medical therapy alone (Control)
Number of subjects: 178
Study 16242437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 20
Study 16242437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% glucose solution)
Number of subjects: 20
Study 12066420 — intervention group
Group type: EXPERIMENTAL
Intervention: Time intervals of 1.85 to 6.45 seconds with a memory task
Number of subjects: 0
Study 10586554 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PEG (propofol/epidural/nitrous oxide)
Number of subjects: 88
Study 10586554 — intervention group
Group type: COMPARATOR
Intervention: Group PE (propofol/epidural)
Number of subjects: 88
Study 8767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (in lipid emulsion) 0.25 mg/kg
Number of subjects: 40
Study 8767241 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1.5 mg/kg
Number of subjects: 40
Study 1897306 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular anti-diphtheria vaccination (incomplete/irregular doses)
Number of subjects: 204
Study 1897306 — intervention group
Group type: COMPARATOR
Intervention: Regular vaccination (three toxoid doses) and one or more booster doses
Number of subjects: 204
Study 1897306 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregularly vaccinated children
Number of subjects: 204
Study 1897306 — intervention group
Group type: EXPERIMENTAL
Intervention: All children (both regular and irregular)
Number of subjects: 204
Study 1897306 — intervention group
Group type: COMPARATOR
Intervention: Regularly or irregularly administered toxoid doses
Number of subjects: 204
Study 6225405 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline
Number of subjects: 0
Study 6225405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0